2014_CALYM.jpg

Presentation

A Carnot Institute devoted to lymphoma: creating synergies, initiating partnerships, accelerating translational research

CALYM consortium brings together 13 leading French research entities with unique preclinical and clinical research expertise in the field of lymphoma. The consortium, with no international equivalent, aims to accelerate innovation and transfer in the field of lymphoma, in the fast growing market of the therapeutic, diagnostic and imaging segments.

  • Non-profit clinical and translational research organizations and 11 high profile public research labs
  • Imaging and pathology central review
  • Biology sampling logistics
  • Early phase trials Phase I (incl. first-in-man) to III (incl. registration)

Consortium overview 

2 non-profit research organizations

  • A world-renowned cooperative group, LYSA (The Lymphoma Study Association)
  • Europe’s leading academic clinical research organization : LYSARC (The Lymphoma Academic Research Organisation)

    LYSA and LYSARC are together accredited «French cooperative intergroup of international dimension in the field of cancer» by the French National Cancer Institute

11 public research labs
(belonging to INSERM or CNRS national research bodies, to universities, and/or to hospitals) having an A+ or A grade from the French Agency for Research and Higher Education Evaluation

 

http://www.calym.org/-Member-entities-.html

A common cancer steadily increasing

Lymphoma is the 6th cancer (5th in the USA) and the most common form of hematological malignancy in the developed world.
Lymphoma is a cancer of the lymphatic ganglions, a proliferation of a subtype of white blood cells called lymphocytes produced by lymphoid organs (lymph nodes, spleen, thymus and bone marrow).

There are two major types of lymphoma:

  • Hodgkin’s lymphoma
  • Non-Hodgkin’s lymphoma (NHL), consisting of about 30 different subtypes NHL are the most frequent hemopathic malignancies (blood cancer) with an incidence rate of 15/100 000 inhabitants/year

The clinical evolution and therapeutic options vary depending on the different types/subtypes of the disease.

Key figures

  • About 2 million people worldwide living with lymphoma
  • More than 70,000 new cases/year reported in Europe
  • 12,000 new cases/year in France (2000)

Lymphoma drug market: attractive and dynamic

  • The global NHL pharmaceutical market was estimated to be worth USD 6.5 billion in 2009 (source: Business Wire) and it is forecasted to grow at a compound annual growth rate of 7.75% to reach USD 11.9 billion by 2017 (source: Innovaro)
  • Lymphoma: number 1 cancer for the number of clinical trials
  • The weight of the biotech industry (20% of marketed drugs and 80% of those undergoing development) will also impact the lymphoma field

Major advances in the treatment of lymphoma, but …

Despite an important improvement in patient survival thanks to immunotherapy since 1997, the demands in R&D are ample in order to achieve solid personalized medicine for lymphoma :

  • More targeted, better tolerated and more effective drugs
  • Improved therapeutic combinations
  • Biological and imaging markers to refine diagnosis and prognosis and to select the population for targeted therapy
  • Accelerated transfer research from bench to bedside
  • Faster clinical studies, especially in the early phases
  • Decreased rate of attrition in clinical research

Current research interests

Expertises and competences

The integrated expertise and competences within CALYM enable to cover all stages of lymphoma research and development of therapeutics and biomarkers, from basic to clinical research.

Four R&D pillars

In order to cover all stages of therapeutic and diagnostic development - from preclinical to clinical - and to answer current unmet medical needs in the lymphoma field, CALYM is organized around four R&D pillars.

Technologies and platforms

  • « Omics » platforms: tumor and host genomics, study of metabolic pathways, caracterization of prognostic or diagnostic markers
  • Flowcytometry platforms, some of which are accredited by IBISA, the French National Infrastructure in Health Biology and Agronomy
  • Imaging platforms : cellular, tissular, viable cells, small animal
  • Platforms for centralized review of pathology and imaging (PET, CT) in clinical trials
  • Histopathology lab devoted to lymphoma: immunohistochemistry, DNA/RNA extraction on paraffin, tissue microarraying …
  • Biological sampling logistics platform and biobanks
  • LYSARC « data management center» (accreditation from the French Cancer Institute) for clinical trials from phase I to phase III-,: regulatory affairs, monitoring, data management, biostatistics, pharmacovigilance, quality assurance…
  • LYSA network of 130+ clinical investigation centers including 6 centers accredited «Early phase clinical trials centers» by the French National Cancer Institute
  • Tools for data digitization (electronic case report form, digital pathology slide scanner, web-based software for loading and central review of clinical imaging)

Assets

  • Animal models
  • Cell lines
  • Original collection of viable cells
  • Biological collections (tissues, plasma, DNA/RNA)
  • Tools for data digitization (electronic case report form, digital pathology slide scanner, web-based software for loading and central review of clinical imaging)
  • Proprietary databases

 

Partnerships

Partners in basic research

The collaborations extend well beyond France to meet global challenges and to be competitive in some highly dynamic areas of research.
CALYM Carnot institute researchers collaborate in large-scale European programs and maintain favored links with universities worldwide.

Industrial Partnerships

In parallel to its fundamental research activity, CALYM Carnot institute conducts applied research together with industrial partners. Common know-how and skills are shared in order to develop new products and services that can benefit to patients.
Several partnerships are ongoing with the industry, see examples in our Portfolio.
These programs leverage both our clinical and our non-clinical expertise to set-up collaborative research with our partners, ranging from fundamental, to clinical, translational and applied research in various domains.

CALYM Carnot institute is sharing its expertises and its technological platforms (see Core Facilities) via the consortium GLOBAL CARE Initiative.

Many partnerships are ongoing with Sanofi-Adventis, Jansen-Cilag, Alizé-Pharma, Lilly, Genzyme, Roche, Pfizer, Johnson&Johnson, Genentech, Millennium, Amgen, Novartis

See our Portfolio

GLOBAL CARE is an outstanding consortium of 5 French expertises :